A Randomized Controlled Study of the Effectiveness of Electrophysiological Monitoring of Dexmedetomidine in Patients with Brain Damage of Various Origins

Cover Page

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Background. At the same time, the main effect of the use of this drug is the elimination of the autonomic nervous system dysfunction and sympatholysis. It seems important to search for a method of indications and selection of a dose of dexmedetomidine in intensive care. Aims — to improve the clinical effectiveness of the electrophysiological navigation of the prolonged use of dexmedetomidine in patients with brain pathology of various origins. Methods. The study included 83 patients 20–50 days after the traumatic brain injury, anoxic damage; consequences of acute disorders of cerebral. 37 patients comprised the 1st intervention group with a clinical course of dexmedetomidine (male — 28; female — 9; average age 49.6 ± 2.3 years) and 46 patients comprised the 2nd control group without pharmacological correction with dexmedetomidine (male — 23; female — 23, average age 51 ± 2.5 years). Criteria for the inclusion of prolonged infusion of the drug dexmedetomidine (Orion Pharma, Finland) are based on heart rate variability (HRV) indicators characteristic of sympathetic hyperactivity, the target task of titration of doses of dexmedetomidine served as the parameters for achieving normal HRV indicators, the appearance of parasympathetic hyperactivity served as the basis for reducing the dosage of the drug or stopping it of application. HRV parameters were recorded before dexmetomedine infusion-initially, on 1–3; 4–5; 9–10; 15–20 days of drug administration. Results. The starting dose of dexmedetomidine with sympathetic hyperactivity in patients was 0.12 to 0.24 μg.kg–1.hr–1 (average dose 0.16 ± 0.01; total 200 mg/day). According to digital data from HRV, the effective dose of dexmedetomidine ED50 was 0.26 ± 0.03 μg.kg–1.hr–1 (total daily 353.8 ± 35.1 μg) and was achieved on day 9–10 using dexmedetomidine. Conclusions. The protective role of dexmedetomidine with correction of sympathetic hyperactivity based on electrophysiological navigation according to the HRV is reliable in the following indicators: The improvement of consciousness; a significant decrease in the incidence of distress lung syndrome; septic shock; mortality.

Full Text

Restricted Access

About the authors

Yuri Y. Kiryachkov

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Author for correspondence.
Email: kirychyu@yandex.ru
ORCID iD: 0000-0001-5113-199X
SPIN-code: 2726-8833


Russian Federation, Moscow

Marina V. Petrova

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology; The Peoples’ Friendship University of Russia

Email: mail@petrovamv.ru
ORCID iD: 0000-0003-4272-0957
SPIN-code: 9132-4190

MD, PhD, Professor

Russian Federation, Moscow

Bagautdin G. Muslimov

Konchalovsky Central City Clinical Hospital

Email: muslimov.bagautdin@mail.ru
ORCID iD: 0000-0002-2941-304X
SPIN-code: 4472-0245


Russian Federation, Moscow

Sergey A. Bosenko

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Email: bosenich@mail.ru
ORCID iD: 0000-0002-9447-0622
SPIN-code: 3285-5759


Russian Federation, Moscow

Mikhail M. Gorlachev

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Email: doc-gorlachov@rambler.ru
ORCID iD: 0000-0002-7277-5193
SPIN-code: 7203-2639


Russian Federation, Moscow


  1. Esterov D, Greenwald BD. Autonomic dysfunction after mild traumatic brain injury. Brain Sci. 2017;11:7(8):100. doi: https://doi.org/10.3390/brainsci7080100
  2. Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16(9):721–729. doi: https://doi.org/10.1016/S1474-4422(17)30259-4
  3. Godo S, Irino S, Nakagawa A, et al. Diagnosis and Management of Patients with Paroxysmal Sympathetic Hyperactivity following Acute Brain Injuries Using a Consensus-Based Diagnostic Tool: A Single Institutional Case Series. Tohoku J Exp Med. 2017;243(1):11–18. doi: https://doi.org/10.1620/tjem.243.11
  4. Baguley IJ, Nicholls JL, Felmingham KL, et al. Dysautonomia after traumatic brain injury: a forgotten syndrome? J Neurol Neurosurg Psychiatry. 1999;67(1):39–43. doi: https://doi.org/10.1136/jnnp.67.1.39
  5. Baguley IJ, Slewa-Younan S, Heriseanu RE, et al. The incidence of dysautonomia and its relationship with autonomic arousal following traumatic brain injury. Brain Inj. 2007;21(11):1175–1181. doi: https://doi.org/10.1080/02699050701687375
  6. Baguley IJ, Nott MT, Slewa-Younan S, et al. Diagnosing dysautonomia after acute traumatic brain injury: evidence for overresponsiveness to afferent stimuli. Arch Phys Med Rehabil. 2009;90(4):580–586. doi: https://doi.org/10.1016/j.apmr.2008.10.020
  7. Mahmoud M, Mason KP. Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. Br J Anaesth. 2015;115(2):171–182. doi: https://doi.org/10.1093/bja/aev226
  8. Jiang L, Hu M, Lu Y, et al. The protective effects of dexmedetomidine on ischemic brain injury: A meta-analysis. J Clin Anesth. 2017; 40:25–32. doi: https://doi.org/10.1016/j.jclinane.2017.04.003
  9. Yamanaka D, Kawano T, Nishigaki A, et al. Preventive effects of dexmedetomidine on the development of cognitive dysfunction following systemic inflammation in aged rats. J Anesth. 2017;31(1):25–35. doi: https://doi.org/10.1007/s00540-016-2264-4
  10. Kanashiro A, Sônego F, Ferreira RG, et al. Therapeutic potential and limitations of cholinergic anti-inflammatory pathway in sepsis. Pharmacol Res. 2017;117:1–8. doi: https://doi.org/10.1016/j.phrs.2016.12.014
  11. Samuel S, Allison TA, Lee K, Choi HA. Pharmacologic management of paroxysmal sympathetic hyperactivity after brain injury. J Neurosci Nurs. 2016;48(2):82–89. doi: https://doi.org/10.1097/JNN.0000000000000207
  12. Wang X, Ji J, Fen L, Wang A. Effects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: a prospective controlled trial. Brain Inj. 2013;27(13–14):1617–1622. doi: https://doi.org/10.3109/02699052.2013.831130
  13. Ding XD, Zheng NN, Cao YY, et al. Dexmedetomidine preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest. Int J Neurosci. 2016;126(3):249–256. doi: https://doi.org/10.3109/00207454.2015.1005291
  14. Wu GJ, Chen JT, Tsai HC, et al. Protection of Dexmedetomidine Against Ischemia/Reperfusion-Induced Apoptotic Insults to Neuronal Cells Occurs Via an Intrinsic Mitochondria-Dependent Pathway. J Cell Biochem. 2017;118(9):2635–2644. doi: https://doi.org/10.1002/jcb.25847
  15. Endesfelder S, Makki H, von Haefen C, et al. Neuroprotective effects of dexmedetomidine against hyperoxia-induced injury in the developing rat brain. PLoS One. 2017;12(2):e0171498. doi: https://doi.org/10.1371/journal.pone.0171498
  16. Akpınar O, Nazıroğlu M, Akpınar H. Different doses of dexmedetomidine reduce plasma cytokine production, brain oxidative injury, PARP and caspase expression levels but increase liver oxidative toxicity in cerebral ischemia-induced rats. Brain Res Bull. 2017;130:1–9. doi: https://doi.org/10.1016/j.brainresbull.2016.12.005
  17. Xu KL, Liu XQ, Yao YL, et al. Effect of dexmedetomidine on rats with convulsive status epilepticus and association with activation of cholinergic anti-inflammatory pathway. Biochem Biophys Res Commun. 2018;495(1):421–426. doi: https://doi.org/10.1016/j.bbrc.2017.10.124
  18. Dardalas I, Stamoula E, Rigopoulos P, et al. Dexmedetomidine effects in different experimental sepsis in vivo models. Eur J Pharmacol. 2019;856:172401. doi: https://doi.org/10.1016/j.ejphar.2019.05.030
  19. Raue JF, Tarvainen MP, Kästner SB. Experimental study on the effects of isoflurane with and without remifentanil or dexmedetomidine on heart rate variability before and after nociceptive stimulation at different MAC multiples in cats. BMC Vet Res. 2019;15(1):258. doi: https://doi.org/10.1186/s12917-019-2004-8
  20. Cho JS, Kim SH, Shin S, et al. Effects of Dexmedetomidine on Changes in Heart Rate Variability and Hemodynamics During Tracheal Intubation. Am J Ther. 2016;23(2):e369–e376. doi: https://doi.org/10.1097/MJT.0000000000000074
  21. Kim MH, Lee KY, Bae SJ, et al. Intraoperative dexmedetomidine attenuates stress responses in patients undergoing major spine surgery. Minerva Anestesiol. 2019;85(5):468–477. doi: https://doi.org/10.23736/S0375-9393.18.12992-0

Supplementary files

There are no supplementary files to display.



Abstract: 527

PDF (Russian): 2

Article Metrics

Metrics Loading ...



Copyright (c) 2020 Russian academy of sciences

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies